FDA vs. EMA: Where GxP Expectations Actually Diverge

By Stéphanie Verbrugghe, Founder & Principal GxP Consultant 10 min read

FDA and EMA requirements converge on quality principles through ICH but diverge on execution. The three differences that matter most are EU batch certification by a Qualified Person, which has no FDA equivalent; the EU Product Quality Review versus the FDA Annual Product Review; and inspection style, where EU inspectors typically work to a scheduled scope and FDA investigators follow the evidence.

Where do the two regimes genuinely agree?

On almost all of the underlying quality thinking. Both expect a pharmaceutical quality system in the sense of ICH Q10, risk management in the sense of ICH Q9, and lifecycle process validation rather than three qualification batches treated as a finish line. Both treat data integrity as foundational and both will escalate hard when records cannot be reconstructed. A well-built quality system satisfies the principles of either regime. This is why sponsors are often lulled: the gap is not conceptual, so it does not surface in a gap analysis conducted at the level of principle. It surfaces in the specific artefacts each regulator expects to be handed.

Which divergences actually cost money?

Batch certification is the largest. EU law requires a named Qualified Person to certify each batch before market release, with personal accountability; there is no FDA analogue, so a US-only operation has no one qualified to perform the step and no procedure describing it. Second, periodic review: the EU Product Quality Review and the FDA Annual Product Review overlap heavily but not exactly, and a single document written for one regulator usually leaves gaps against the other. Third, the qualified person's role in supply chain oversight of active substance manufacture is read more strictly in the EU, which turns supplier qualification records into an inspection focus rather than a filing appendix.

Key takeaway

The gap between FDA and EMA is not conceptual, which is exactly why gap analyses miss it. It lives in the specific artefacts each inspector expects to be handed.

Does passing one inspection predict passing the other?

Not reliably, because the two inspectorates work differently. EU GMP inspections are commonly scheduled, scoped in advance and conducted against a defined plan, which rewards organisations whose documentation is complete and navigable. FDA investigators more often follow the evidence where it leads, expanding scope when a thread looks loose, which rewards organisations whose day-to-day practice matches their procedures under unscripted questioning. A site can be genuinely strong at one and weak at the other. The practical implication is that mock inspections should be run in the style of the regulator you are actually expecting.

Frequently asked questions

Does a Mutual Recognition Agreement mean one inspection covers both?

The EU–US MRA allows each authority to rely on the other's GMP inspection findings for certain human medicines, which reduces duplicate inspections. It does not harmonise the underlying requirements, and it does not remove the EU obligation for QP batch certification.

Can one quality manual serve both regimes?

Yes, and it usually should. What has to be handled deliberately is the small set of region-specific procedures — batch certification, periodic review format, recall and reporting timelines — which are best written as regional annexes to a single core system rather than as two parallel manuals that drift apart.

Which regulator is stricter?

Neither, usefully. They are strict about different things and in different ways. Treating one as a superset of the other is the error; the correct posture is to identify the specific artefacts each expects and make sure both sets exist.

Sources

  1. EudraLex Volume 4, Annex 16 — Certification by a Qualified Person and batch release, European Commission. health.ec.europa.eu
  2. 21 CFR Part 211 — Current Good Manufacturing Practice for Finished Pharmaceuticals, US Food and Drug Administration. ecfr.gov

Pending scientific review. This briefing summarises published regulatory guidance and has not yet been signed off by a named subject-matter expert. Verify against the primary sources below before relying on it.

Preparing for an inspection on the other side of the Atlantic?

We run mock inspections in the style of the regulator you are actually expecting, using consultants who have worked inside both systems.

Explore audits and mock inspections ➔